Recently, the Enhancer of zeste homolog 2 (EZH2) inhibitor tazemetostat received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with solid malignancies and hematologic cancers (Straining and Eighmy, 2022). This evidence concerns the gene EZH2 and hematopoietic and lymphoid cell neoplasm.